Skip to content

Study · Non-randomized trial · n = 12 · 2004

5 results

A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients.

van der Hoek J, de Herder WW, Feelders RA, van der Lely AJ, Uitterlinden P, Boerlin V, Bruns C, Poon KW, Lewis I, Weckbecker G, Krahnke T, Hofland LJ, Lamberts SW

The Journal of clinical endocrinology and metabolism1 Feb 2004Cited by 93 (Europe PMC)

PMID14764775 (opens in a new tab)DOI10.1210/jc.2003-031052 (opens in a new tab)PepBankPUB-14764775
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In acromegaly patients, glucose was initially slightly elevated after octreotide compared with the control day.

    In plain wordsIn acromegaly patients, glucose initially increased slightly after octreotide compared with the control day.

    Peptide
    Octreotide
    Outcome
    IncreaseGlucose
    Study

    n = 12

    Comparator
    control day
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    100 microg · subcutaneous · single doseAs given in this study (human).

    Source sentences

    Summary
    Glucose levels were initially slightly elevated after octreotide and SOM230, compared with control day, whereas insulin levels were only significantly suppressed by octreotide.
    1 context sentence
    Summary · context
    In a single-dose, proof-of-concept study, 100 microg octreotide and 100 and 250 microg SOM230 were given s.c. to 12 patients with active acromegaly.
  2. 02HumanNon-randomized trialEfficacy outcome

    In acromegaly patients, octreotide significantly suppressed insulin compared with the control day.

    In plain wordsIn acromegaly patients, octreotide reduced insulin compared with the control day.

    Peptide
    Octreotide
    Outcome
    DecreaseInsulin
    Study

    n = 12

    Comparator
    control day
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    100 microg · subcutaneous · single doseAs given in this study (human).

    Source sentences

    Summary
    Glucose levels were initially slightly elevated after octreotide and SOM230, compared with control day, whereas insulin levels were only significantly suppressed by octreotide.
    1 context sentence
    Summary · context
    In a single-dose, proof-of-concept study, 100 microg octreotide and 100 and 250 microg SOM230 were given s.c. to 12 patients with active acromegaly.
  3. 03HumanNon-randomized trialEfficacy outcome

    In eight acromegaly patients, octreotide and SOM230 produced comparable GH suppression (-65 +/- 7 versus -72 +/- 7%).

    In plain wordsIn eight acromegaly patients, octreotide and SOM230 suppressed GH similarly.

    Peptide
    Octreotide
    Outcome
    Not applicableGH level change in eight patients
    Study

    n = 8

    Comparator
    250 microg SOM230
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    100 microg · subcutaneous · single doseAs given in this study (human).

    Measurements

    GH change
    −65%
    octreotide 100 microg; reported +/- 7
    GH change
    −72%
    SOM230 250 microg; reported +/- 7

    Source sentences

    Summary
    A comparable suppression of GH levels by octreotide and 250 microg SOM230 was observed in eight patients (-65 +/- 7 vs. -72 +/- 7%, respectively).
    1 context sentence
    Summary · context
    In a single-dose, proof-of-concept study, 100 microg octreotide and 100 and 250 microg SOM230 were given s.c. to 12 patients with active acromegaly.
  4. 04HumanNon-randomized trialEfficacy outcome

    In three acromegaly patients, GH suppression was weaker with octreotide than SOM230 (-17 +/- 15 versus -70 +/- 2%, P < 0.01).

    In plain wordsIn three acromegaly patients, octreotide suppressed GH less than SOM230.

    Peptide
    Octreotide
    Outcome
    IncreaseGH level change in three patients
    Study

    n = 3

    Comparator
    250 microg SOM230
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    100 microg · subcutaneous · single doseAs given in this study (human).

    Measurements

    GH change
    −17%
    octreotide 100 microg; reported +/- 15
    GH change
    −70%
    SOM230 250 microg; reported +/- 2

    Source sentences

    Summary
    In three patients, the acute GH-lowering effect of 250 microg SOM230 was significantly superior to that of octreotide (-70 +/- 2 vs. -17 +/- 15%, respectively; P < 0.01).
    1 context sentence
    Summary · context
    In a single-dose, proof-of-concept study, 100 microg octreotide and 100 and 250 microg SOM230 were given s.c. to 12 patients with active acromegaly.
  5. 05HumanNon-randomized trialEfficacy outcome

    In one acromegaly patient, octreotide lowered GH more than SOM230.

    In plain wordsIn one acromegaly patient, octreotide lowered GH more than SOM230.

    Peptide
    Octreotide
    Outcome
    DecreaseGH level change in one patient
    Study

    n = 1

    Comparator
    SOM230
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    100 microg · subcutaneous · single doseAs given in this study (human).

    Source sentences

    Summary
    In one patient, the GH-lowering effect of octreotide was better than that of SOM230.
    1 context sentence
    Summary · context
    In a single-dose, proof-of-concept study, 100 microg octreotide and 100 and 250 microg SOM230 were given s.c. to 12 patients with active acromegaly.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 2

    27 Oct 2026, 16:36 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.